BioSpace News Archive

Roche’s Tecentriq (atezolizumab) combined with Avastin (bevacizumab) met the primary efficacy endpoint in early-stage hepatocellular carcinoma in the Phase III IMbrave050 study.

bluebird bio, Inc. is expecting gross proceeds of $120 million with its newly announced public offering of 20,000,000 shares.

Jazz Pharmaceuticals and Zymeworks announced results from a Phase II trial of the latter’s HER2-targeted antibody for metastatic gastroesophageal adenocarcinoma.

Editas announced the sale of its iPSC-derived iNK programs to Shoreline Biosciences. Shoreline also licensed Editas’ SLEEK technology.

Johnson & Johnson discontinued the Phase III trial of an investigational HIV vaccine regimen Wednesday after an independent review showed it was ineffective at preventing disease.

ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that Joseph Eid M.D. has been appointed as a Non-Executive Director of the Company, with effect from 19 January 2023.

XNK Therapeutics AB announced the appointment of Dr. Peter Hovstadius as Chief Medical Officer, effective immediately.

Immunovia announced it is realigning its Swedish operations with its strategic priorities to drive R&D productivity and focus on the US commercialization of the IMMray™ PanCan-d test.

Prenetics Global Limited a leader in genomic and diagnostic testing, announced an executive leadership change to ensure the company realizes the full potential of its broad genetics and digital testing platform and as a commitment to the EMEA market.

FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a Clinical Trial Application for a planned Phase-1 clinical trial for LUCID-MS, a candidate for the treatment of Multiple Sclerosis.